Targeting the renin‐angiotensin system: Potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis
Silvia Sookoian, Carlos J. Pirola – 2 December 2011
Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes‐associated protein–mediated activation
Raquel Urtasun, Maria U. Latasa, Maria I. Demartis, Stella Balzani, Saioa Goñi, Oihane Garcia‐Irigoyen, Maria Elizalde, Maria Azcona, Rosa M. Pascale, Francesco Feo, Paulette Bioulac‐Sage, Charles Balabaud, Jordi Muntané, Jesus Prieto, Carmen Berasain, Matias A. Avila – 2 December 2011 – The identification of molecular mechanisms involved in the maintenance of the transformed phenotype of hepatocellular carcinoma (HCC) cells is essential for the elucidation of therapeutic strategies.
Radiofrequency ablation of high‐grade dysplastic nodules
Yun Ku Cho, Jin Wook Chung, Yoonjung Kim, Hyun Je Cho, Soo Hyun Yang – 2 December 2011 – High‐grade dysplastic nodules (HGDNs) are known to be premalignant lesions of hepatocellular carcinoma (HCC). We devised a model to estimate the long‐term survival benefit of treating HGDNs by radiofrequency ablation (RFA) (Group I), as compared with regular follow‐up and timely treatment by resection (Group II). A hypothetical 60‐year‐old compensated patient with cirrhosis was assumed.
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell, Chunfu Wang, Jin‐Hua Sun, Donald R. O'Boyle, Peter Nower, Lourdes Valera, Dike Qiu, Susan Roberts, Xin Huang, Bernadette Kienzle, Marc Bifano, Richard E. Nettles, Min Gao – 2 December 2011 – The NS5A replication complex inhibitor, BMS‐790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single‐ascending dose study and a 14‐day multiple‐ascending dose (MAD) monotherapy study.
Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta
Katia Bourd‐Boittin, Dominique Bonnier, Anthony Leyme, Bernard Mari, Pierre Tuffery, Michel Samson, Frédéric Ezan, Georges Baffet, Nathalie Theret – 2 December 2011
Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases
Silvia Ruiz‐Gaspà, Angels Martinez‐Ferrer, Nuria Guañabens, Marta Dubreuil, Pilar Peris, Anna Enjuanes, Maria Jesús Martinez de Osaba, Luisa Alvarez, Ana Monegal, Andrés Combalia, Albert Parés – 2 December 2011 – Low bone formation is considered to be the main feature in osteoporosis associated with cholestatic and end‐stage liver diseases, although the consequences of retained substances in chronic cholestasis on bone cells have scarcely been studied.
Peribiliary cysts
David Da Ines, Wassim Essamet, Pierre F. Montoriol – 2 December 2011
Dendritic cells take on more tasks in the liver?
Jeremy S. Duffield – 26 November 2011
Hepatitis C and non‐Hodgkin lymphoma: The clinical perspective
Sidonie K. Hartridge‐Lambert, Eytan M. Stein, Arnold J. Markowitz, Carol S. Portlock – 26 November 2011 – Hepatitis C virus (HCV) is a commonly transmitted infection that has both hepatic and extrahepatic repercussions. These range from the inflammatory to the oncologic with an undisputed link to hepatitis, liver cirrhosis, and hepatocellular carcinoma. Its role in the development of B cell non‐Hodgkin lymphoma (B‐NHL) is becoming better understood, leading to opportunities for research, therapy, and even prevention.
Role of low‐density lipoprotein receptor in the hepatitis C virus life cycle
Anna Albecka, Sandrine Belouzard, Anne Op de Beeck, Véronique Descamps, Lucie Goueslain, Justine Bertrand‐Michel, François Tercé, Gilles Duverlie, Yves Rouillé, Jean Dubuisson – 26 November 2011 – Hepatitis C virus (HCV) particles are known to be in complex with lipoproteins. As a result of this interaction, the low‐density lipoprotein (LDL) receptor (LDLR) has been proposed as a potential entry factor for HCV; however, its implication in virus entry remains unclear.